NY-ESO-1TCR/dnTGFBRII Engineered T Cells therapy (The University Of Chicago)

N/A

Report date: 2026/02/06 20:01:23

Base Information

Drug NameNY-ESO-1TCR/dnTGFBRII Engineered T Cells therapy (The University Of Chicago)
Drug Alias NameNY-ESO-1 TCR/ dnTGFβRII
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionT lymphocyte replacementsCancer/testis antigen 1 modulators
TargetsCancer/testis antigen 1
Therapy Area/IndicationsSolid tumoursOvarian Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Chicago
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Chicago
Inactive CompaniesN/A
Active IndicationsSolid tumoursOvarian Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A